Literature DB >> 31767252

[Pathogenesis of non-alcoholic fatty liver disease].

Rodolphe Anty1, Philippe Gual2.   

Abstract

Non-Alcoholic Fatty Liver Disease (NAFLD) is a complex chronic disease resulting from an interaction between genetic and environmental factors. The phenotype and pathophysiology of NAFLD is heterogeneous. NAFLD is a continuum of histological lesions of the liver from steatosis, Non-Alcoholic SteatoHepatitis (NASH), NASH with fibrosis, cirrhosis to hepatocellular carcinoma. The pathophysiology encompasses a dysfunction in fatty tissue (sub-cutaneous and visceral) associated with insulin-resistance and metabolic inflammation. NAFLD is a "multi-systemic" disease. Reciprocal and aggravating interactions exist between NAFLD, cardiovascular anomalies and diabetes. The understanding of the mechanisms responsible for NAFLD allows the identification of potential novel therapeutic targets.
Copyright © 2019. Published by Elsevier Masson SAS.

Entities:  

Mesh:

Year:  2019        PMID: 31767252     DOI: 10.1016/j.lpm.2019.09.051

Source DB:  PubMed          Journal:  Presse Med        ISSN: 0755-4982            Impact factor:   1.228


  8 in total

1.  Berberine attenuates non-alcoholic steatohepatitis by regulating chemerin/CMKLR1 signalling pathway and Treg/Th17 ratio.

Authors:  Zengsheng Lu; Fengbin Lu; Liyan Wu; Beihui He; Zhiyun Chen; Maoxiang Yan
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2020-06-10       Impact factor: 3.000

2.  Croton urucurana Baill. Ameliorates Metabolic Associated Fatty Liver Disease in Rats.

Authors:  Pablo Alvarez Auth; Gustavo Ratti da Silva; Eduarda Carolina Amaral; Victor Fajardo Bortoli; Mariana Inocencio Manzano; Lauro Mera de Souza; Evellyn Claudia Wietzikoski Lovato; João Tadeu Ribeiro-Paes; Arquimedes Gasparotto Junior; Francislaine Aparecida Dos Reis Lívero
Journal:  Front Pharmacol       Date:  2022-05-20       Impact factor: 5.988

3.  ENO3 promoted the progression of NASH by negatively regulating ferroptosis via elevation of GPX4 expression and lipid accumulation.

Authors:  Di Lu; Qiaoyun Xia; Zhiyu Yang; Shanjun Gao; Suofeng Sun; Xiaoying Luo; Zhen Li; Xiulei Zhang; Shuangyin Han; Xiuling Li; Mingbo Cao
Journal:  Ann Transl Med       Date:  2021-04

4.  Effects of renalase deficiency on liver fibrosis markers in a nonalcoholic steatohepatitis mouse model.

Authors:  Katsuyuki Tokinoya; Nanami Sekine; Kai Aoki; Seiko Ono; Tomoaki Kuji; Takehito Sugasawa; Yasuko Yoshida; Kazuhiro Takekoshi
Journal:  Mol Med Rep       Date:  2021-01-26       Impact factor: 2.952

Review 5.  Monounsaturated Fatty Acids in Obesity-Related Inflammation.

Authors:  Gaetan Ravaut; Alexandre Légiot; Karl-F Bergeron; Catherine Mounier
Journal:  Int J Mol Sci       Date:  2020-12-30       Impact factor: 5.923

6.  Understanding Mechanisms Underlying Non-Alcoholic Fatty Liver Disease (NAFLD) in Mental Illness: Risperidone and Olanzapine Alter the Hepatic Proteomic Signature in Mice.

Authors:  Bahman Rostama; Megan Beauchemin; Celeste Bouchard; Elizabeth Bernier; Calvin P H Vary; Meghan May; Karen L Houseknecht
Journal:  Int J Mol Sci       Date:  2020-12-08       Impact factor: 5.923

Review 7.  Non-alcoholic fatty liver disease (NAFLD) as a neglected metabolic companion of psychiatric disorders: common pathways and future approaches.

Authors:  Óscar Soto-Angona; Gerard Anmella; María José Valdés-Florido; Nieves De Uribe-Viloria; Andre F Carvalho; Brenda W J H Penninx; Michael Berk
Journal:  BMC Med       Date:  2020-10-01       Impact factor: 8.775

8.  Efficacy and Safety of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.

Authors:  Yuan Zhu; Jiao Xu; Dong Zhang; Xingyu Mu; Yi Shi; Shangtao Chen; Zengxiang Wu; Shuangqing Li
Journal:  Front Endocrinol (Lausanne)       Date:  2021-12-09       Impact factor: 5.555

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.